Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant and clinically meaningful improvement in main goal for its gastric or ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced the launch of Project EVEREST—a groundbreaking ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with ...

Enhertu + pertuzumab showed significant PFS improvement vs. THP in HER2+ metastatic breast cancer in DESTINY-Breast09 trial. Interim OS data favored Enhertu combo; safety profile aligned with ...

AstraZeneca will record sales in other countries worldwide, for which profits shared with Daiichi Sankyo will be recorded within cost of sales. Daiichi Sankyo will manufacture and supply DS-1062.

Daiichi Sankyo and AstraZeneca have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for Enhertu (fam-trastuzumab deruxtecan-nxki). Enhertu is a ...

Daiichi Sankyo and AstraZeneca have initiated three Phase III clinical trials to evaluate the efficacy and safety of datopotamab deruxtecan (Dato-DXd)-based combinations in patients with advanced ...

AstraZeneca, which is partnered with Daiichi Sankyo on the drug, has cited Dato-DXd as one of the products that will help it achieve its goal of nearly doubling its revenue to $80 billion by 2030.

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care ...